Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Pietros Fight
AddedFeb 18, 2024
UpdatedJun 28, 2026
Pietros Fight

Pietros Fight

Pietro's Fight funds translational research for Duchenne Muscular Dystrophy, accelerating clinical trials and potential cures.

HQ
Grand Island, NY, US
Founded
2012
Overview
Compare
Employees
Website

Founded with the core mission of combating Duchenne Muscular Dystrophy (DMD), Pietro's Fight is dedicated to raising awareness and funding translational research aimed at finding a cure for this fatal genetic disorder. The organization focuses on moving scientific discoveries from the lab to human clinical trials, ensuring that children like Pietro have the opportunity to lead full lives. By collaborating with leading scientists globally, Pietro's Fight aims to accelerate the development of effective treatments and potential cures for DMD.

Notable individuals affiliated with Pietro's Fight include leading scientists and researchers in the field of muscular dystrophy. The organization has successfully raised significant funds, which have been instrumental in advancing several promising clinical trials. Pietro's Fight has made a substantial impact by not only funding critical research but also by fostering a global community dedicated to eradicating Duchenne Muscular Dystrophy.

Pietros Fight - Quick Facts

When was Pietros Fight founded?

Pietros Fight was founded in 2012.

Where is Pietros Fight's headquarters located?

Pietros Fight's headquarters is located in Grand Island, NY, US.

How many employees does Pietros Fight have?

Pietros Fight has 5 employees as of Feb 4, 2024.

Pietros Fight - Classification

Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Donations
Customer
  • Non-Profit
Main Product
  • Research Funding
Tags
  • Healthtech